Last reviewed · How we verify

NCT04860661: EKET

Esketamine on Postpartum Depression in Cesarean Section Women

Completed NA Last updated 6 August 2024
What this trial tests

NA trial testing Esketamine in Esketamine in 336 participants. Completed in 31 March 2024.

Timeline
1 May 2021
Primary endpoint
31 March 2024
31 March 2024

Quick facts

Lead sponsorAilin Luo
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposeprevention
Enrollment336
Start date1 May 2021
Primary completion31 March 2024
Estimated completion31 March 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Ailin Luo — full company profile →

Who can join

Adults 18 to 40, female only, with Esketamine or Postpartum Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial.
    Chu T, Peng X, Wan K, Li M, et al · · 2026 · PMID 41607308 · DOI 10.1097/eja.0000000000002348

Verify or expand the search:

Other trials of Esketamine

Trials testing the same drug.

Other recruiting trials for Esketamine

Currently open trials in the same condition.

Other Ailin Luo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04860661.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing